Vanguard Asset Management’s Corcept Therapeutics CORT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.5M Buy
99,826
+5,916
+6% +$636K 0.01% 658
2026
Q2
$8.17M Buy
93,910
+9,426
+11% +$569K 0.01% 808
2026
Q1
$3.41M Buy
+84,484
New +$3.16M ﹤0.01% 1163

Other funds holding CORT

Vanguard Asset Management's CORT Position: Q3 2026 in Review

Vanguard Asset Management increased its Corcept Therapeutics (CORT) stake by 6.3% in Q3 2026, buying an estimated $636K and bringing the position to 99,826 shares worth $11.5M. The position accounts for 0.01% of the portfolio, ranked #658.

Vanguard Asset Management first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 501 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

  • Vanguard Asset Management held 99,826 shares of Corcept Therapeutics worth $11.5M as of Q3 2026.
  • Vanguard Asset Management bought 5,916 Corcept Therapeutics shares in Q3 2026, an estimated $636K.
  • Corcept Therapeutics made up 0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #658 holding.
  • Vanguard Asset Management first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 501 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.